

【 For Immediate Release 】

19 February 2020

**Vincent Medical Holdings Limited**

永勝醫療控股有限公司

Stock Code : 1612. HK

Obtained NMPA approval for O₂FLO Respiratory Unit

(Hong Kong, 19 February 2020) – **Vincent Medical Holdings Limited** (“Vincent Medical” or together with its subsidiaries, the “Group”, stock code: 1612) is pleased to announce that its O₂FLO Respiratory Unit (with model number: **VUN-001**, the “Unit”) has received approval from the National Medical Products Administration (“NMPA”) of the PRC, along with its related accessories and disposables. Following the approval from Japan’s Ministry of Health, Labour, and Welfare and Conformité Européenne (“CE”) Mark, this represented yet another successful registration for the same device, as the Group continued to drive its OBM development while transforming into a comprehensive respiratory medical device provider for both disposables and equipment.

The Unit, a non-invasive high flow oxygen therapy device, is used in the treatment of patients with chronic or acute respiratory distress such as pneumonia, viral pneumonia, chronic obstructive pulmonary disease, heart failure, and asthma. It has been clinically proven that the utilization of high flow oxygen therapy can improve oxygenation, reduce the patient’s work of breathing and serve as a more economical and safer alternative to invasive mechanical ventilation. Apart from the PRC, Japan and the European Union, the Group is also committed to registering and launching the device in the United States and other countries.

- End -



About Vincent Medical Holdings Limited (Stock code: 1612)

Established in 1997, Vincent Medical Holdings Limited is a Hong Kong-headquartered medical device manufacturing group. We develop, manufacture and sell a wide range of medical devices to our customers around the globe, focusing on respiratory care, imaging disposable, and orthopaedic and rehabilitation products which satisfy international quality assurance standards. Our products include a range of electronic medical devices such as high-flow oxygen therapy devices, respiratory humidification systems, sleep ventilators, rehabilitation devices, as well as the related disposables in respiratory care and anesthesiology. With our production base in Dongguan, China, along with the R&D and regulatory divisions in Dongguan Songshan Lake Technology Industrial Park and Hong Kong Science and Technology Park, we are dedicated to bringing innovative, high-quality and reliable medical devices to the market.

This press release is issued by DLK Advisory Limited on behalf of **Vincent Medical Holdings Limited**.

For enquiries, please contact:



DLK Advisory 金通策略

Jonathan Lam (jonathanlam@dlkadvisory.com)

Kathleen Mui (kathleenmui@dlksadvisory.com)

Jason Ng (jasonng@dlkadvisory.com)

Tel: +852 2857 7101

Fax: +852 2857 7103